[{"from": "human", "value": "Could you provide a description of this molecule? [C][N][Branch1][C][C][C][C][N][Branch1][C][C][C][=C][C][=Branch2][Branch1][C][=C][Branch1][N][C][=C][Ring1][=Branch1][N][C][=Branch1][C][=O][C][=C][N][C][=N][C][=C][C][=Branch1][Ring2][=N][Ring1][=Branch1][C][=C][N][Branch1][O][C][=C][C][=C][C][=C][Ring1][=Branch1][Ring1][=Branch2][C][C][Branch1][C][F][Branch1][C][F][F][O][C]"}, {"from": "gpt", "value": "The molecule is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, befotertinib specifically binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. Compared to some other EGFR inhibitors, befotertinib may have therapeutic benefits in tumors with T790M-mediated drug resistance. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization."}]